Blue Jet Healthcare IPO has opened for subscription today (Wednesday, October 25) and will closes on Friday, October 27. Blue Jet Healthcare IPO raised a capital of ₹252.08 crore through an anchor book process, where 22 investors took part in the anchor book offering, on Monday, October 23. Blue Jet Healthcare IPO is completely a offer for sale (OFS) of 24,285,160 equity share; there is no fresh issue component, according to RHP. Blue Jet Healthcare IPO size is ₹840.27 crore. The company's promoters are Shiven Akshay Arora, Akshay Bansarilal Arora, and Archana & Akshay Arora. Shiven Akshay Arora will sell up to 5,918,849 equity shares, while Akshay Bansarilal Arora will sell up to 18,366,311 equity shares.Blue Jet Healthcare IPO has reserved not more than 50% of the shares in the public issue for Qualified Institutional Buyers (QIB), not less than 15% for Non Institutional Investors (NII), and not less than 35% of the offer is reserved for Retail Investors.
Key Risks:
- A decline in their demand for the company's products, the loss of one or more of these clients, or a worsening of their financial situation or prospects could all have a negative impact on the business's operations, financial situation, and cash flows. A sizable amount of the company's operating revenue comes from sales in Europe and the US, two regulated markets; third, the business, its financial situation, and its future prospects will all suffer if new products are not successfully introduced to the market on time. They failed to timely file their audited consolidated financial statements for the 2020 fiscal year, and any delays in complying with regulations could have a negative impact on their company. Non-compliance with and changes in environmental, health and safety and labor laws, or accidents giving rise to civil or criminal liabilities, may adversely affect the business, results of operations, financial condition and reputation. Acquisitions of and investments in other companies, businesses, properties or technologies could result in operating difficulties, dilution and other adverse consequences.The company is currently entitled to certain incentive schemes. Any decrease in or discontinuation of such schemes may affect its results of operations. The company highlighted that if it inadvertently infringe on the patents or intellectual property rights of others, it may be subjected to legal action and its business and reputation may be adversely affected. If the company enters into certain related party transactions in the ordinary course of the business and it cannot assure you that such transactions will not have an adverse effect on its results of operation and financial condition. A fall in India's credit ratings could have an impact on the equity share price on the external front.The company may not be able to transfer cost increases to clients in proportionately if inflation increases in India, which could result in a fall in profits. Regardless of the company's operating performance, fluctuations in the value of its equity shares could be negatively impacted by changes in the exchange rate between the Indian Rupee and other currencies.
Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Blue Jet Healthcare share price was indicated at ₹400 apiece, which is 15.61% higher than the IPO price of ₹346.
Based on last 9 sessions grey market activities, today IPO GMP trending upward and expects a strong listing. The lowest GMP is ₹0, while the highest GMP is ₹95.
'Grey market premium' indicates investors' readiness to pay more than the issue price.
You must be logged in to post a comment.